N-Terminal-pro-Brain Natriuretic Peptide Is Increased and Closely Related with Osteoporosis in Patients with Newly Diagnosed Primary Hyperparathyroidism

Mehmet Akif Erdol; Begüm Şeyda Avcı; Hilmi Erdem Sümbül

doi:10.54614/eurjther.2022.0064

Authors

Mehmet Akif Erdol Department of Cardiology, Health Sciences University, Ankara City Hospital, Ankara, Turkey https://orcid.org/0000-0002-2721-440X
Begüm Şeyda Avcı Department of Internal Medicine, Health Sciences University, Adana City Research and Training Hospital, Adana, Turkey https://orcid.org/0000-0001-6149-9341
Hilmi Erdem Sümbül Department of Internal Medicine, Health Sciences University, Adana City Research and Training Hospital, Adana, Turkey https://orcid.org/0000-0002-7192-0280

DOI:

https://doi.org/10.54614/eurjther.2022.0064

Keywords:

Primary hyperparathyroidism, osteoporosis, NT-proBNP

Abstract

Objective: The aim of this study is to determine the prevalence of osteopenia and osteoporosis in newly diagnosed primary hyperparathyroidism patients and to evaluate the relationship between the presence of osteoporosis and the primary hyperparathyroidism routine laboratory parameters including N-terminal-pro-brain natriuretic peptide. Methods: This prospective study included 94 patients (mean age: 59.7 ± 11.7 years, female/male: 78/16) who have been diagnosed with primary hyperparathyroidism. For all patients participating in this study, laboratory tests were performed (routine tests and tests for diagnosing hyperparathyroidism), and dual-energy x-ray absorptiometry inspections were also performed. The participants of the study were divided into 3 groups according to T score in dual-energy X-ray absorptiometry as normal (group I or T score >−1), patients with osteopenia (group II or T score between −1 and −2.5), and the patients with osteoporosis (group III or T score ≤ −2.5). Results: Notable level increase of blood urea nitrogen and N-terminal-pro-brain natriuretic peptide from group I to group III is seen in the results. In logistic regression analysis, it was found that levels of N-terminal-pro-brain natriuretic peptide and urine calcium independently determined the patients for osteoporosis (P < .05). According to the analysis, it was found that increasing levels of urine calcium (per 10 mg/day) and N-terminal-pro-brain natriuretic peptide (per 10 pg/mL) increase the risk of osteoporosis by 8.6% and 9.1% for patients, respectively. When we took N-terminal-pro-brain natriuretic peptide and urine calcium cut-off values as 200 pg/mL and 300 mg/day, respectively, it determines patients for osteoporosis with 82.6% sensitivity and 73.2% specificity, and 73.9% sensitivity and 63.4% specificity, respectively. N-terminalpro-brain natriuretic peptide and urinary calcium levels were independently associated with T score in dual-energy X-ray absorptiometry. Conclusion: The primary outcome of this study is N-terminal-pro-brain natriuretic peptide levels are significantly increased in newly diagnosed primary hyperparathyroidism patients and are independently associated with osteoporosis presence. In addition, apart from N-terminal-pro-brain natriuretic peptide level, urine calcium level is also independently associated with osteoporosis presence, in our study

Metrics

Metrics Loading ...

References

Demirtas D, Sumbul HE, Demirtas AO, et al. Morning blood pressure surge increases in patients with hypertensive primary hyperparathyroidism and is independently associated with serum calcium level. Clin Exp Hypertens. 2020;42(1):86-92.

Sumbul HE, Koc AS. The abdominal aortic intima-media thickness increases in patients with primary hyperparathyroidism. Exp Clin Endocrinol Diabetes. 2019;127(6):387-395.

Valdemarsson S, Lindergård B, Tibblin S, Bergenfelz A. Increased biochemical markers of bone formation and resorption in primary hyperparathyroidism with special reference to patients with mild disease. J Intern Med. 1998;243(2):115-122.

Vestergaard P, Mollerup CL, Frøkjaer VG, Christiansen P, BlichertToft M, Mosekilde L. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ. 2000;321(7261):598-602.

Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop. J Clin Endocrinol Metab. 2014;99(10):3561-3569.

Leere JS, Kruse C, Robaczyk M, Karmisholt J, Vestergaard P. Associations between trabecular bone score and biochemistry in surgically vs conservatively treated outpatients with primary hyperparathyroidism: a retrospective cohort study. Bone Rep. 2018;9:101-109.

Eller-Vainicher C, Filopanti M, Palmieri S, et al. Bone quality, as measured by trabecular bone score, in patients with primary hyperparathyroidism. Eur J Endocrinol. 2013;169(2):155-162.

Walker MD, Saeed I, Lee JA, et al. Effect of concomitant vitamin D deficiency or insufficiency on lumbar spine volumetric bone mineral density and trabecular bone score in primary hyperparathyroidism. Osteoporos Int. 2016;27(10):3063-3071.

Manzanares. World congress on osteoporosis, osteoarthritis and musculoskeletal diseases (WCO-IOF-ESCEO 2014): poster abstracts. Osteoporos. 2014;25:159-440.

Lee JH, Kim JH, Hong AR, Kim SW, Shin CS. Skeletal effects of vitamin D deficiency among patients with primary hyperparathyroidism. Osteoporos Int. 2017;28(5):1667-1674.

Almqvist EG, Becker C, Bondeson AG, Bondeson L, Svensson J, Svensson SE. Increased plasma concentrations of N-terminal pro-B-type natriuretic peptide in patients with mild primary hyperparathyroidism. Clin Endocrinol (Oxf). 2006;65(6):760-766.

Ogard CG, Engelmann MD, Kistorp C, Nielsen SL, Vestergaard H. Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf). 2005;63(5):493-

Agarwal G, Nanda G, Kapoor A, et al. Cardiovascular dysfunction in symptomatic primary hyperparathyroidism and its reversal after curative parathyroidectomy: results of a prospective case control study. Surgery. 2013;154(6):1394-403.

Verheyen N, Fahrleitner-Pammer A, Belyavskiy E, et al. Relationship between bone turnover and left ventricular function in primary hyperparathyroidism: the EPATH trial. PLoS ONE. 2017;12(4):e0173799.

De Feo ML, Bartolini O, Orlando C, et al. Natriuretic peptide receptors regulate endothelin synthesis and release from parathyroid cells. Proc Natl Acad Sci U S A. 1991;88(15):6496-6500.

Mestek ML, Weil BR, Greiner JJ, Westby CM, DeSouza CA, Stauffer BL. Osteopenia and endothelin-1-mediated vasconstrictor tone in postmenopausal women. Bone. 2010;47(3):542-545.

Muratli HH, Celebi L, Hapa O, Biçimoğlu A. Comparison of plasma endothelin levels between osteoporotic, osteopenic and normal subjects. BMC Musculoskelet Disord. 2005;6:49.

Gulhan I, Kebapcilar L, Alacacioglu A, et al. Postmenopausal women with osteoporosis may be associated with high endothelin-1. Gynecol Endocrinol. 2009;25(10):674-678.

Bushinsky DA, Monk RD. Electrolyte quintet: calcium. Lancet. 1998;352(9124):306-311.

Rolighed L, Rejnmark L, Sikjaer T, et al. Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J Clin Endocrinol Metab. 2014;99(3):1072-1080.

Walker MD, Cong E, Lee JA, et al. Vitamin D in primary hyperparathyroidism: effects on clinical, biochemical, and densitometric presentation. J Clin Endocrinol Metab. 2015;100(9):3443-3451.

Leistner DM, Seeger FH, Fischer A, et al. Elevated levels of the mediator of catabolic bone remodeling RANKL in the bone marrow environment link chronic heart failure with osteoporosis. Circ Heart Fail. 2012;5(6):769-777.

Terrovitis J, Zotos P, Kaldara E, et al. Bone mass loss in chronic heart failure is associated with secondary hyperparathyroidism and has prognostic significance. Eur J Heart Fail. 2012;14(3):326-332.

Lyons KJ, Majumdar SR, Ezekowitz JA. The unrecognized burden of osteoporosis-related vertebral fractures in patients With heart failure. Circ Heart Fail. 2011;4(4):419-424.

Sakhaee K, Maalouf NM, Poindexter J, Adams-Huet B, Moe OW. Relationship between urinary calcium and bone mineral density in patients with calcium nephrolithiasis. J Urol. 2017;197(6):1472-1477.